| Name | Title | Contact Details |
|---|
Zynex, Inc. is a medical device manufacturer that produces and markets electrotherapy devices for use in pain management, physical rehabilitation, neurological diagnosis and cardiac monitoring.
McKesson Corporation, currently ranked 7th on the FORTUNE 500, we are a global healthcare services and medical supply company dedicated to delivering better care. We support the entire healthcare system, including pharmacies, hospitals, health systems, biotech and life sciences companies, specialty care and oncology practices, physician offices, surgery centers, and long-term care and home health facilities. We deliver pharmaceutical products, medical supplies and business services to each of these groups to create a world of better health.
The Harvard Drug Group is a Livonia, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RHEI Pharmaceuticals is a Plainsboro, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Momenta is a biotechnology company with a product pipeline of both complex mixture generic and novel drugs. Our complex mixture generics and follow-on biologics effort is focused on building a thorough understanding of the structure-process-activity of complex mixture drugs to develop generic versions of marketed products. While we use a similar analytical and development approach across all of our product candidates, we tailor that approach for each specific product candidate. Our first objective is to apply our core analytical technology to thoroughly characterize the structure of the marketed product. By defining the chemical composition of multiple batches of a marketed product, we are able to develop an equivalence window which captures the inherent variability of the innovator`s manufacturing process. Using this information, we then build an extensive understanding of the structure-process relationship to design and control our manufacturing process to manufacture reproducibly an equivalent version of the marketed product. Where necessary, and as required by the U.S. Food and Drug Administration, or FDA, we will supplement an application with additional supportive structure-activity data (e.g., immunogenicity, pharmacodynamics). Our goal is to obtain FDA approval for and commercialize generic or follow-on versions of complex mixture products, thereby providing high quality, safe and affordable medicines to patients in need.